Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer

Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillips, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, S. Gail Eckhardt

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences